rs2523506 — DDX39B

Regulatory variant in the 5' UTR of DDX39B (RNA helicase/mRNA export factor) that reduces DDX39B translation, impairing IL7R exon 6 inclusion and increasing soluble IL7R — the strongest known epistatic interaction in MS genetics

See your personal result for DDX39B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

DDX39B — The RNA Helicase Gating Autoimmune Risk

Deep in the MHC class III region on chromosome 6, the gene DDX39B (also known as BAT1) encodes an RNA helicase with a central role in mRNA export, pre-mRNA splicing, and nuclear export of immune transcripts. A 2017 landmark study in Cell established that a regulatory variant at rs2523506 reduces DDX39B protein production, and that this reduction propagates through a chain of molecular events to increase the risk of multiple sclerosis (MS) — the first rigorous demonstration of biological epistasis in humans. The discovery matters not just for MS genetics but as a proof of concept: two common variants in separate genes, each with modest individual effects, combine to produce a dramatically elevated risk that neither alone explains.

The Mechanism

DDX39B is a DEAD-box RNA helicase11 DEAD-box RNA helicase
A family of enzymes that use ATP hydrolysis to unwind RNA secondary structures and remodel RNA-protein complexes, enabling downstream RNA processing steps. One of its critical functions is promoting the inclusion of IL7R exon 622 IL7R exon 6
Exon 6 of the IL7R gene encodes a transmembrane anchor; when included, IL7R is expressed on the T cell surface as a membrane-bound receptor. When skipped, the resulting mRNA produces a soluble, secreted form that cannot signal properly during pre-mRNA splicing. When exon 6 is properly included, the interleukin-7 receptor (IL7R) anchors to the T cell surface and signals for T cell survival and differentiation. When exon 6 is skipped, the mRNA encodes a soluble IL7R (sIL7R)33 soluble IL7R (sIL7R)
The secreted form acts as a decoy receptor, sequestering IL-7 away from surface IL7R and dysregulating T cell homeostasis isoform that is secreted rather than membrane-bound, dysregulating IL-7 signaling in ways that predispose to autoimmunity.

The rs2523506 T allele (reported as "A" on the coding/minus strand in the original paper) lies in the 5' untranslated region of DDX39B. This regulatory change reduces the translational efficiency44 translational efficiency
How efficiently a cell's ribosomes convert DDX39B mRNA into DDX39B protein; a less efficient 5' UTR means fewer protein molecules are produced from the same amount of mRNA of DDX39B mRNA — cells with the T allele produce less DDX39B protein. With less DDX39B helicase available, the spliceosome is less able to promote IL7R exon 6 inclusion, and exon 6 skipping increases. This cascade — T allele → less DDX39B protein → more exon 6 skipping → more soluble IL7R → impaired IL-7 signaling → dysregulated T cell homeostasis — provides the mechanistic basis for the variant's MS association.

Subsequent research has broadened the picture considerably. A 2023 eLife study showed that DDX39B is also essential for proper splicing of FOXP3, the master transcription factor of regulatory T cells (Tregs). When DDX39B is depleted, FOXP3 introns are retained, FOXP3 protein is lost, and Treg function collapses — providing a second immune tolerance mechanism under DDX39B control. A 2024 mechanistic study confirmed that DDX39B's ATPase activity (not its helicase activity per se) is required for efficient pre-spliceosome assembly at FOXP3 introns, and demonstrated that MS susceptibility genes are disproportionately enriched among genes affected by DDX39B depletion (p = 0.00013). DDX39B thus emerges as a broad guardian of immune gene splicing, with the T allele at rs2523506 chronically reducing this protection.

The Evidence

Galarza-Muñoz et al. 201755 Galarza-Muñoz et al. 2017
Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk. Cell 169(1):72-84 is the primary study. The team conducted genetic association analysis, reporter assays for translational efficiency, and splicing experiments in primary CD4+ T cells and lymphoblastoid cell lines. Key findings: (1) the DDX39B 5' UTR T allele reduces translation in reporter assays, (2) DDX39B depletion causes increased IL7R exon 6 skipping preferentially in the context of the IL7R risk allele (rs6897932 C allele), and (3) carriers of both risk alleles — the DDX39B T allele and the IL7R C allele — show a combined OR of approximately 2.75 for MS, substantially exceeding what either variant contributes alone.

The epistatic architecture is critical to understand. The IL7R rs6897932 C allele reduces exon 6 splicing efficiency intrinsically (the exon splice site is weaker). The DDX39B T allele reduces the level of the helicase that compensates for this weakness. Together, they remove both the intrinsic and compensatory mechanisms for exon 6 inclusion — a synthetic depletion that explains why the combined genotype confers dramatically elevated risk whereas either alone produces more modest effects.

The 2023 FOXP3 finding (Hirano et al. 202366 Hirano et al. 2023
The RNA helicase DDX39B activates FOXP3 RNA splicing to control T regulatory cell fate. eLife 12) extends this model: MS susceptibility genes are substantially enriched among transcripts sensitive to DDX39B levels (empirical p = 0.00013), suggesting the T allele impairs a broad immune-regulatory splicing program rather than a single target.

The variant maps to chromosome 6p21.3, within the MHC class III region — a genomic area with some of the highest density of immune-related genes in the human genome. Its position in this region means it may co-segregate with other MHC haplotype-specific effects, which complicates precise effect-size estimation but is consistent with strong evolutionary selection pressure on this locus.

Practical Implications

No pharmacological intervention exists that specifically compensates for reduced DDX39B expression. The actionable implications for T allele carriers center on early awareness and monitoring for MS and related autoimmune conditions, and on avoiding environmental triggers that compound autoimmune risk.

MS is a complex disease requiring multiple hits — genetic, environmental (low vitamin D, Epstein-Barr virus infection, smoking, obesity, shift work disrupting circadian rhythms), and stochastic. The T allele is common enough (~16% frequency in Europeans) that most carriers will never develop MS. Nevertheless, the combined double-risk genotype at rs2523506 and rs6897932 confers an OR of approximately 2.75, placing double-risk carriers in a higher-surveillance population.

Modifiable risk factors for MS that are well-supported by evidence include: maintaining adequate serum 25(OH)D (≥50 nmol/L; high-dose D supplementation in MS-risk populations has been studied in clinical trials), avoiding smoking (one of the strongest MS environmental risk factors), maintaining a healthy BMI in adolescence and early adulthood, and — given the EBV connection — awareness that EBV seroconversion in adolescence substantially increases MS risk in genetically susceptible individuals.

Interactions

The defining interaction is between rs2523506 (DDX39B) and rs6897932 (IL7R). These two variants act in the same molecular pathway: DDX39B promotes IL7R exon 6 inclusion; the IL7R rs6897932 C allele weakens the exon 6 splice site. When DDX39B levels are low (T allele at rs2523506) and the splice site is already weak (C allele at rs6897932), exon 6 skipping becomes nearly complete, maximizing sIL7R production and MS risk. This is the epistatic pair described in the 2017 Cell paper with combined OR ≈ 2.75.

This compound interaction is the most important clinical finding — the individual SNP results for rs2523506 are substantially amplified when rs6897932 genotype is known. See the compound action in consolidated_actions.yml for the combined recommendation.

Genotype Interpretations

What each possible genotype means for this variant.

GG Protective DDX39B Expression Normal

No DDX39B expression reduction — normal IL7R splicing and immune tolerance function

You carry two copies of the G allele at rs2523506, the common genotype associated with normal DDX39B translational efficiency. Your cells produce a full complement of DDX39B RNA helicase, maintaining efficient IL7R exon 6 inclusion and proper IL-7 receptor signaling. About 70% of people globally share this genotype. In the absence of a co-occurring risk allele at IL7R rs6897932, your DDX39B-IL7R pathway is functioning without the epistatic risk described in the 2017 Cell study.

GT Partial DDX39B Reduction Intermediate

One T allele — reduced DDX39B translation and mildly impaired IL7R exon 6 splicing

With one T allele, your DDX39B expression falls between the GG (full) and TT (lowest) states. In primary CD4+ T cells and lymphoblastoid cell lines from the Galarza-Muñoz 2017 study, heterozygous cells showed intermediate levels of IL7R exon 6 inclusion relative to homozygotes. The additive architecture of this variant means one T allele shifts the distribution of IL7R splicing outcomes — more sIL7R is produced than in GG individuals, but less than in TT individuals.

Because DDX39B also controls FOXP3 splicing (Hirano et al. 2023, eLife), partial DDX39B reduction may also modestly impair regulatory T cell (Treg) development and function, contributing to a broader autoimmune susceptibility beyond MS specifically.

The key clinical question is your IL7R rs6897932 genotype: if you also carry the IL7R C risk allele, the two variants act synergistically to deplete IL7R exon 6 inclusion beyond what either alone achieves. The 2017 Cell paper documented this compound risk at OR ≈ 2.75.

TT Lowest DDX39B Expression High Risk

Two T alleles — maximum DDX39B expression reduction, highest sIL7R production, elevated MS risk

The TT genotype places maximum pressure on the IL7R exon 6 splicing pathway. In the Galarza-Muñoz 2017 study, DDX39B was identified as a "potent activator" of IL7R exon 6 inclusion. TT homozygotes produce the least DDX39B protein from this 5' UTR translational efficiency effect. This lowest-DDX39B state is most consequential when the IL7R splice site itself is also impaired — precisely the situation when the IL7R rs6897932 C allele is present.

Beyond MS, the 2023 eLife study (Hirano et al.) demonstrated that DDX39B level is a critical determinant of FOXP3 mRNA splicing and thus regulatory T cell (Treg) fate. With chronically low DDX39B (as in TT), FOXP3 intron retention increases, reducing FOXP3 protein and impairing Treg-mediated immune tolerance. The 2024 mechanistic study (Nagasawa et al.) confirmed that MS susceptibility genes are strongly enriched among transcripts sensitive to DDX39B levels (p = 0.00013), suggesting TT individuals may have broader susceptibility to autoimmune conditions whose triggering genes are also DDX39B-sensitive.

MS risk is not determined by genetics alone — environmental factors (Epstein-Barr virus seroconversion timing, vitamin D status, smoking, BMI, shift work) interact with genetic susceptibility. The TT genotype is best understood as a susceptibility amplifier that reduces the threshold at which environmental triggers produce pathological immune dysregulation.